09:07 AM EDT, 08/06/2025 (MT Newswires) -- Viridian Therapeutics ( VRDN ) reported Q2 net loss Wednesday of $1.00 per share, widening from a loss of $0.77 a year earlier.

Analysts polled by FactSet expected a loss of $1.00 per share.

Total revenue for the quarter ended June 30 was $75,000, compared with $72,000 a year earlier.

Analysts surveyed by FactSet expected $100,000.

The company said that as of June 30, it had $563.4 million in cash, cash equivalents, and short-term investments, which is expected to fund operations into H2 2027.

Shares of the company were up 1.3% in recent Wednesday premarket activity.